Sarpogrelate
- Generic Name
- Sarpogrelate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO6
- CAS Number
- 125926-17-2
- Unique Ingredient Identifier
- 19P708E787
- Background
Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.
- Indication
用于改善慢性动脉闭塞症所引起的溃疡、疼痛及冷感等缺血性症状。
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 148
- Registration Number
- NCT06046196
- Locations
- 🇰🇷
GangNeung Asan Hospital, Gangneung-si, Gangwon-do, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 1003
- Registration Number
- NCT05083299
- Locations
- 🇰🇷
BuKyung Kim, Busan, Korea, Republic of
Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02607436
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT02294643
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Sarpogrelate Drug Interaction
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 9
- Registration Number
- NCT02097511
- Locations
- 🇰🇷
Ajou University School of Medicine, Suwon, Gyeonggi, Korea, Republic of
Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Korea United Pharm. Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01841086
The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT01674686
- Locations
- 🇰🇷
Hyoen-Cheol Gwon, MD,PhD, Seoul, Korea, Republic of
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
- Conditions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Aichi Gakuin University
- Target Recruit Count
- 20
- Registration Number
- NCT01548274
- Locations
- 🇯🇵
Aichi-Gakuin University, Nagoya, Aichi, Japan
Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 36
- Registration Number
- NCT01429688
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 36
- Registration Number
- NCT01421563
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.